- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tanespimycin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Interventions
- GVV858, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
- Conditions
- Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Interventions
- Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
- Interventions
- Abemaciclib, Niraparib Tosylate Monohydrate
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Localized Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Metastatic Breast Cancer
- Interventions
- Best Practice, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Buffalo, New York • Cleveland, Ohio
- Conditions
- Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
- Interventions
- letrozole, quality-of-life assessment, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Rochester, Minnesota
- Conditions
- Cancer
- Interventions
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
- Biological · Genetic · Other + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 8
- States / cities
- Cleveland, Ohio
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
- Interventions
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Up to 49 Years · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- H. Kim Lyerly
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Durham, North Carolina
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
- Interventions
- MM-310
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1259
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
- Interventions
- Motexafin Gadolinium
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cetuximab, bortezomib
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer
- Interventions
- poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 192
- States / cities
- Palo Alto, California • Pleasanton, California • Aurora, Colorado + 123 more
- Conditions
- Breast Cancer, Hot Flashes, Hot Flushes
- Interventions
- soy protein, isoflavones, Tamoxifen, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 14
- States / cities
- Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Interventions
- Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Harold J. Burstein, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts
- Conditions
- Breast Neoplasms, Metastases, Neoplasm
- Interventions
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey
- Conditions
- Depression, Post-traumatic Stress Disorder, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- support group therapy, educational intervention
- Procedure · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Nevada City, California • Stanford, California
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment, Lifestyle Counseling, Semaglutide
- Procedure · Other · Behavioral + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 46 Years to 55 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- flow cytometry, laboratory biomarker analysis, Data Collection
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee